DDI Study Between Dorzagliatin and Rifampicin

A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics and Safety of Dorzagliation Administered Alone or in Combination With Rifampicin in Healthy Subjects

The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.

Inclusion Criteria:

• Body weight ≥ 50 kg (male) or ≥ 45 kg (female)
• BMI within 19～26 kg/m2

Exclusion Criteria:

• History or disease status that may impact the ADME of the study
• Use of any drugs, OTCs, or hebal within 4 weeks of screening
• Drug abuse
• Blood donation